Showing 4951-4960 of 6808 results for "".
- Study: Omega-3 Supplementation Reduces Acne Severityhttps://practicaldermatology.com/news/study-omega-3-supplementation-reduces-acne-severity/2467299/New research suggests there may be potential benefits of omega-3 fatty acids (ω-3 FA) in managing acne severity through dietary intervention and supplementation. Study researchers publishing in the Journal of Cosmetic Dermatology focused their efforts on eicosapentaenoic acid (EP
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://practicaldermatology.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- PD-1 Gene Variants Linked to Melanoma Riskhttps://practicaldermatology.com/news/pd-1-gene-variants-linked-melanoma-risk/2467088/A recent study has highlighted significant associations between specific single nucleotide variants (SNVs) in the PD-1 and PD-L1 genes and the risk of metastatic melanoma (MM). Researchers conducted the study at IRCCS Ospedale Policlinico San Martino in Genova, Italy, and included 125 patients wi
- DermTech Files for Voluntary Chapter 11 Protectionhttps://practicaldermatology.com/news/dermtech-files-voluntary-chapter-11-protection/2467087/DermTech announced it has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company’s strategic alternatives review process. DermTech, which is a provider of noninvasive skin genomics technol
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro